tiprankstipranks
SciSparc Ltd. (SPRC)
NASDAQ:SPRC
US Market

SciSparc Ltd. (SPRC) Price & Analysis

Compare
173 Followers

SPRC Stock Chart & Stats


---

Financials

Quarterly

Ownership Overview

0.13%99.87%
Insiders
Mutual Funds
0.13% Other Institutional Investors
99.87% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

SPRC FAQ

What was SciSparc Ltd.’s price range in the past 12 months?
SciSparc Ltd. lowest stock price was $0.20 and its highest was $2.10 in the past 12 months.
    What is SciSparc Ltd.’s market cap?
    SciSparc Ltd.’s market cap is $3.04M.
      When is SciSparc Ltd.’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were SciSparc Ltd.’s earnings last quarter?
      SciSparc Ltd. released its earnings results on Dec 03, 2018. The company reported -$0.012 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.012.
        Is SciSparc Ltd. overvalued?
        According to Wall Street analysts SciSparc Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does SciSparc Ltd. pay dividends?
          SciSparc Ltd. does not currently pay dividends.
          What is SciSparc Ltd.’s EPS estimate?
          SciSparc Ltd.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does SciSparc Ltd. have?
          SciSparc Ltd. has 10,828,251 shares outstanding.
            What happened to SciSparc Ltd.’s price movement after its last earnings report?
            SciSparc Ltd. reported an EPS of -$0.012 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
              Which hedge fund is a major shareholder of SciSparc Ltd.?
              Currently, no hedge funds are holding shares in SPRC
              ---

              Company Description

              SciSparc Ltd.

              SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              ACADIA Pharmaceuticals
              Neurocrine
              SAGE Therapeutics
              Anavex Life Sciences
              Axsome Therapeutics
              Popular Stocks
              ---
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis